Navigation Links
MGI Pharma Announces Positive Results from a Pivotal Phase 3 Study,of Aquavan Injection in Patients Undergoing Bronchoscopy

ate consistent results for the 6.5 mg/kg initial bolus dose of Aquavan and describe a predictable and effective therapeutic sedation profile in patients with a wide range of heath status and comorbidities who are undergoing a variety of common procedures," said Mary Lynne Hedley, Ph.D., Executive Vice President and Chief Scientific Officer of MGI PHARMA. "We remain on track to submit the Aquavan NDA to the FDA early in the third quarter of this year."

Bronchoscopy Results Consistent with Previously-Reported Colonoscopy Data

The results of this study are consistent with the data previously reported from a pivotal phase 3 study of Aquavan in 312 patients undergoing colonoscopy. The primary endpoint of the colonoscopy trial was also sedation success, and additional endpoints included treatment success and measures of physician and patient satisfaction. In the colonoscopy trial, among patients treated with an initial bolus dose of 6.5 mg/kg of Aquavan, the sedation success rate was 86.7% compared to 25.5% among patients treated with an initial bolus control dose of 2.0 mg/kg of Aquavan (p less than 0.001). Based upon the ASA Physical Status Classification System, 31% of patients in this study were classified as P1 (having no known systemic disease), 65% were classified as P2, 4% were classified as P3, and none were classified as P4. One patient in this study experienced hypoxia after receiving midazolam subsequent to administration of a bolus dose of 6.5 mg/kg Aquavan, which resolved following verbal stimulation.

Minor Surgery Safety Study Results

A single arm, open label study was conducted in 123 patients undergoing a variety of minor surgical procedures to assess the safety and tolerability of Aquavan at a dose of 6.5 mg/kg in a variety of settings including arthroscopy, bunionectomy, dilation and curettage, endoscopy, hysteroscopy, lithroscopy, shunt placement and trans-esophageal echoes. Results of this study also describe a predictable
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
(Date:3/27/2015)... According to a new market ... Advanced, Ultrasound), Ablation Catheter (Cryoablation, RF, Microwave), Lab Devices ... WPW) - Global Forecasts to 2019 ", published by MarketsandMarkets, ... ~$4.73 Billion by 2019 with a CAGR of around ... Browse   90   ma rket ...
(Date:3/27/2015)... , March 27, 2015 As ... shipments of incontinence devices for women. ... the most gratifying part is the hundreds of ... women whose lives have been positively impacted by ... of InControl. InControl recently released Apex, ...
(Date:3/27/2015)... The International Myeloma Foundation (IMF) – improving ... toward prevention and a cure – today commended Representative ... resolution (H. Res. 174) that supports the designation of ... Awareness Month." Currently there are more than ... 110,000 new cases are diagnosed yearly, according to the ...
Breaking Medicine Technology:Electrophysiology (EP) Market Worth $4.73 Billion by 2019 2Electrophysiology (EP) Market Worth $4.73 Billion by 2019 3Electrophysiology (EP) Market Worth $4.73 Billion by 2019 4InControl Medical Surpasses 40,000 Shipments Of Incontinence Devices For Women 2The International Myeloma Foundation (IMF) Secures the Introduction of a Federal Resolution Recognizing March 2015 as "National Multiple Myeloma Awareness Month" 2
... May 5 OrthoAccel Technologies, Inc. announced that it has entered ... to introduce the AcceleDent System to the Australian market. , ... (Logo: http://www.newscom.com/cgi-bin/prnh/20091029/DA01250LOGO ) , ... AcceleDent, an acceleration device to enhance orthodontics, was introduced ...
... Instrumentation Laboratory (IL) today announced total worldwide sales in 2009 ... growth v. previous year in current, and 13.2% in local currencies.  In ... growth in local currencies was 13.2% and 12.4%, respectively. , ... "In spite of the major economic downturn, ...
Cached Medicine Technology:OrthoAccel Technologies, Inc. and AB Orthodontics Announce Partnership and Australian Product Introduction 2OrthoAccel Technologies, Inc. and AB Orthodontics Announce Partnership and Australian Product Introduction 3OrthoAccel Technologies, Inc. and AB Orthodontics Announce Partnership and Australian Product Introduction 4Instrumentation Laboratory Achieves Record Sales in 2009 2Instrumentation Laboratory Achieves Record Sales in 2009 3
(Date:3/27/2015)... USA (PRWEB) March 27, 2015 According ... rates of newborns born with Neonatal Abstinence Syndrome (NAS) ... NAS will undergo the painful withdrawal process for a ... body tremors, excessive crying, diarrhea, and vomiting. The condition ... undergoing drug and alcohol addiction treatment (and employing medically ...
(Date:3/27/2015)... 2015 GrassrootsHealth, an international nonprofit public ... (POC) NOW! vitamin D demonstration project April 7 in ... Carolina (MUSC), and will soon follow with a second ... cost to a minimum of 500 pregnant women at ... two service areas. The project will include patient and ...
(Date:3/27/2015)... Operatic contenders and their avid audience will be in ... acclaimed baritone Sherrill Milnes will be overseeing the grand ... Merion in Evanston. The event is the culmination of ... from around the country. “This is a highly-anticipated yearly ... in the country,” said Margaret Gergen, executive director of ...
(Date:3/27/2015)... March 27, 2015 Approximately 300 ... Healthy Kids Coalition Lobby Day to lobby for ... Improvement Program (SHIP). Everlast Climbing was especially ... Bill SF343/HF498 which would strengthen physical education programs ... assessments and other measures to strengthen physical education ...
(Date:3/27/2015)... Airy Jeanine is a rising star. ... video for her debut song “Mama’s Girl”, launched on ... abstract styling effects, the thematic video for the rhythmic ... and assorted outlets. It will be integral in establishing, ... full-scale marketing strategy. The video promotion campaign spearheaded by ...
Breaking Medicine News(10 mins):Health News:In Florida Only 10% of Pregnant Mothers Are Referred to Drug Rehab Despite Testing Positive for Narcotics 2Health News:GrassrootsHealth Moves Vitamin D into Practice with Pregnant Women 2Health News:GrassrootsHealth Moves Vitamin D into Practice with Pregnant Women 3Health News:GrassrootsHealth Moves Vitamin D into Practice with Pregnant Women 4Health News:Opera Idol Competition At The Merion In Evanston 2Health News:Everlast Climbing Advocates to Strengthen Physical Education in Minnesota Schools 2Health News:Airy Jeanine Releases ‘’Mama’s Girl” Official Music Video 2
... Affirming its commitment,to preventing drunken driving tragedies ... has voted unanimously,to endorse the Ensign John R. ... HERO Campaign is a non-profit grassroots organization dedicated ... prevent drunken driving.,It was established by the family ...
... 12 A consumer,group today released a ... Jonathan,Gruber supporting mandatory purchase of private insurance ... Americans are "over-insured" and to,defend the affordability ... for Taxpayer and Consumer Rights, (FTCR),critique of ...
... mean yearly changes in formula , , TUESDAY, Feb. 12 (HealthDay ... to control noroviruses -- a common cause of stomach flu ... to be changed every year because the viruses evolve quickly ... suggests. , Noroviruses infect cells after attaching to histo-blood group ...
... PSI, a leading provider of child,support enforcement services ... contract with the Ohio Department of Job and ... services for the State --,a program the company ... run,for an initial period of one-and-a-half years with ...
... aimed at reducing cross contaminations including Norovirus and ... ... Fla., Feb. 12 Seal Shield LLC announced,that it has begun ... the SILVER SEAL(TM) Keyboard is the,world,s first computer keyboard to be ...
... The Generic Pharmaceutical,Association (GPhA) Board of Directors today named ... the election of William Marth,President and CEO of Teva ... Mr. Marth has 30 years of experience in ... is among the top 20,pharmaceutical companies in the world ...
Cached Medicine News:Health News:National Lt. Governors Association Endorses HERO Campaign; 1st National Association of State Elected Officials Supporting Grassroots Designated Driving Program 2Health News:Consumer Group Finds Use of Outdated Data and Other Major Flaws in Economist's Defense of Mandatory Purchase of Private Health Insurance 2Health News:Vaccine Could Cut Bouts With Stomach Flu 2Health News:Ohio Selects Policy Studies Inc. (PSI) to Continue Operating Its New Hire Reporting Program 2Health News:Seal Shield Ships New SILVER SEAL(TM) Washable, Antimicrobial Keyboard 2Health News:GPhA Announces 2008-2009 Executive Committee; Teva North America's Bill Marth Elected as Chairman of the Board 2
... OraQuick is an FDA ... venipuncture whole blood test used ... of HIV-1 infection. This CLIA ... presence of antibodies to HIV-1, ...
... QuickVue+ Infectious Mononucleosis test is ... antibodies in serum, plasma or whole ... utilizes an extract of bovine erythrocytes ... specificity than similar extracts prepared from ...
... the first available point-of-care diagnostic test that ... of influenza A and B. The test ... an enzyme that assists viral replication by ... infected cells. The ZstatFlu substrate is labeled ...
The NOW Flu A test is the most frequently adopted rapid flu test on the market today. Testing could not be easier and the results are available in 15 minutes. Now you can focus on the results and tre...
Medicine Products: